Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
SYNALGOS-DC is a fixed-dose combination oral capsule containing aspirin, caffeine, and dihydrocodeine bitartrate, a Schedule II opioid analgesic. It is indicated for the relief of moderate pain where the combination of opioid and non-opioid analgesics provides superior efficacy. The caffeine enhances analgesic effect while the aspirin provides anti-inflammatory benefit.
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30%), the brand team is likely in sustainment or transition mode with smaller headcount.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on SYNALGOS-DC offers limited career growth opportunities due to its LOE-approaching status and minimal linked job openings. This role is best suited for professionals focused on defensive commercialization, operational efficiency, or transition planning rather than innovation or rapid advancement.
Worked on SYNALGOS-DC at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.